VTYX
Ventyx Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About VTYX
Ventyx Biosciences, Inc.
A biotechnology company focused on developing novel small molecule therapeutics for inflammatory and autoimmune diseases
12790 El Camino Real, Suite 200, San Diego, California 92130
--
Ventyx Biosciences, Inc., was incorporated in Delaware on November 21, 2018. The company is a clinical-stage biopharmaceutical company focused on developing new therapies for millions of patients with inflammatory and autoimmune diseases. The company believes that their ability to selectively modulate key immune targets to create differentiated drugs will make it possible for them to disrupt the mature multi-billion dollar commercial market and make them a leader in the immunology market.
Company Financials
EPS
VTYX has released its 2025 Q3 earnings. EPS was reported at -0.32, versus the expected -0.45, beating expectations. The chart below visualizes how VTYX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
